![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Disclosure Policy of the Astellas Group for Information on Conduct and Results of Clinical Trials.
The Astellas Group (*1) (hereinafter collectively “Astellas”) recognises that making clinical trial information and results more widely available to researchers, healthcare professionals, patients, and...
Clinical Trials
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO
Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Clinical Trials
CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial
CTI BioPharma Corp. announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive...
Clinical Trials
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Merck known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational...
Clinical Trials
Enox Biopharma, LTD. Announces First Enrollments of A Phase 1a/lb Clinical Trial
Enox Biopharma, Ltd., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections announced today the enrollment of the first...
Clinical Trials
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III trials in cancer pain.
Sativex (nabiximols) is derived from cannabis and usually used to treat the symptoms of multiple sclerosis (MS). This trial was testing the drug for...
Clinical Trials
TxCell announces start of phase IIb clinical trial with Ovasave(R) for refractory Crohn’s disease
TxCell undertaking one of largest ever controlled studies for a personalized T cell immunotherapy product . Top line results of this study are...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read